Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise
Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.
Viatris Inc. (VTRS) Q4 2023 Earnings Call Transcript
Viatris Inc. (VTRS) Q4 2023 Earnings Call Transcript
Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates
Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.
Viatris (VTRS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics com...
Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?
Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.
Insights Into Viatris (VTRS) Q4: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates fo...
From Euphoria To Reality: Viatris' Tale Of Market Whirlwind
Viatris is an American pharmaceutical company formed as a result of the merger of Mylan and Upjohn. Over the past two and a half months, Viatris' share price has risen by more than 38%. Viatris' di...
Viatris Inc. (VTRS) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
Viatris Inc. (VTRS) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
Viatris Stock Is Dirt Cheap And Worth Buying
Viatris shares had a negative 25% total return in the past 2 years, underperforming the S&P 500. The decline is likely due to the company's debt burden and stagnant revenues. Despite this, now may ...
Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip
Viatris (VTRS) third-quarter earnings beat estimates. While brands maintain business, the Complex generics business performs below management's expectations.
Viatris Inc. (VTRS) Q3 2023 Earnings Conference Call Transcript
Viatris Inc. (NASDAQ:VTRS ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants William Szablewski - Head of Global Capital Markets Scott Smith - CEO Rajiv Malik - Pre...
Viatris (VTRS) Beats Q3 Earnings Estimates
Viatris (VTRS) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.86 per share a year ago.
Viatris core profit beats on generic drugs strength
Viatris beat Wall Street estimates for third-quarter core profit on Tuesday, helped by strength in its generic drug portfolio, sending its shares up about 2% in extended trading.
Should You Buy Viatris (VTRS) Ahead of Earnings?
Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?
Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.
Related Companies